Details of the Drug

General Information of Drug (ID: DMLSUWZ)

• Drug Name: PSI-7977
• Synonyms: 1190307-88-0; SOVALDI; PSI 7977; GS-7977; GS 7977; UNII-WJ6CA3ZU8B; WJ6CA3ZU8B; CHEBI:85083; Sofosbuvir (PSI-7977, GS-7977); Hepcvir; Hepcinat; HSDB 8226; 2-((5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-ylmethoxy)phenoxyphosphorylamino)propionic acid isopropyl ester; Sofosbuvir [USAN:INN]; Resof; SoviHep; Sovaldi (TN); Sofosbuvir (JAN/USAN); Sofosbuvir(PSI-7977); GTPL7368; SCHEMBL2010114; CHEMBL1259059; AMMD00019; EX-A389; MolPort-028-720-482; isopropyl (2S)-2-[[[(2R,

Indication

Disease Entry	ICD 11	Status	REF
HCV 1-6 infection	1E51	Approved	[1]
Hepatitis C virus infection	1E51.1	Phase 2	[2]

• Affected Organisms: Hepatitis C Virus
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 3:
  Molecular Weight (mw); 529.5
  Logarithm of the Partition Coefficient (xlogp); 1
  Rotatable Bond Count (rotbonds); 11
  Hydrogen Bond Donor Count (hbonddonor); 3
  Hydrogen Bond Acceptor Count (hbondacc); 11
• Chemical Identifiers:
  Formula: C22H29FN3O9P
  IUPAC Name: propan-2-yl (2S)-2-[[[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate
  Canonical SMILES: C[C@@H](C(=O)OC(C)C)N[P@](=O)(OC[C@@H]1[C@H]([C@@]([C@@H](O1)N2C=CC(=O)NC2=O)(C)F)O)OC3=CC=CC=C3
  InChI: InChI=1S/C22H29FN3O9P/c1-13(2)33-19(29)14(3)25-36(31,35-15-8-6-5-7-9-15)32-12-16-18(28)22(4,23)20(34-16)26-11-10-17(27)24-21(26)30/h5-11,13-14,16,18,20,28H,12H2,1-4H3,(H,25,31)(H,24,27,30)/t14-,16+,18+,20+,22+,36-/m0/s1
  InChIKey: TTZHDVOVKQGIBA-IQWMDFIBSA-N
• Cross-matching ID:
  PubChem CID: 45375808
  ChEBI ID: CHEBI:85083
  CAS Number: 1190307-88-0
  UNII: WJ6CA3ZU8B
  DrugBank ID: DB08934
  TTD ID: D0D4YZ
  INTEDE ID: DR1495
  ACDINA ID: D00634

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)	TTMVBWH	POLG_HCV1	Modulator	[3]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Carboxylesterase 1 (CES1)	DEB30C5	EST1_HUMAN	Substrate	[4]
Adenosine 5'-monophosphoramidase (HINT1)	DEWJATF	HINT1_HUMAN	Substrate	[4]

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from PSI-7977 (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Arn-509	DMT81LZ	Major	Accelerated clearance of PSI-7977 due to the transporter induction by Arn-509.	Acute myeloid leukaemia [2A60]	[5]
Erdafitinib	DMI782S	Moderate	Decreased clearance of PSI-7977 due to the transporter inhibition by Erdafitinib.	Bladder cancer [2C94]	[6]
Tucatinib	DMBESUA	Moderate	Decreased clearance of PSI-7977 due to the transporter inhibition by Tucatinib.	Breast cancer [2C60-2C6Y]	[7]
PF-06463922	DMKM7EW	Major	Accelerated clearance of PSI-7977 due to the transporter induction by PF-06463922.	Lung cancer [2C25]	[5]
Lasmiditan	DMXLVDT	Moderate	Decreased clearance of PSI-7977 due to the transporter inhibition by Lasmiditan.	Migraine [8A80]	[8]
Fostamatinib	DM6AUHV	Moderate	Decreased clearance of PSI-7977 due to the transporter inhibition by Fostamatinib.	Thrombocytopenia [3B64]	[9]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Carmellose sodium	E00625	Not Available	Disintegrant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Magnesium stearate	E00208	11177	lubricant
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Water	E00035	962	Solvent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Sofosbuvir 400 mg tablet	400 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
• [2] 2011 Pipeline of Pharmasset.
• [3] Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
• [4] Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977. J Biol Chem. 2010 Nov 5;285(45):34337-47.
• [5] Cerner Multum, Inc. "Australian Product Information.".
• [6] Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
• [7] Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
• [8] Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
• [9] Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.